Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are effective for obese patients with type 2 diabetes mellitus (T2DM) because they concomitantly target obesity and dysglycaemia. Considering the high prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with T2DM, we determined the...
Gespeichert in:
| Veröffentlicht in: | PloS one 2012-12, Vol.7 (12), p.e50117 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 12 |
| container_start_page | e50117 |
| container_title | PloS one |
| container_volume | 7 |
| creator | Cuthbertson, Daniel J Irwin, Andrew Gardner, Chris J Daousi, Christina Purewal, Tej Furlong, Niall Goenka, Niru Thomas, E Louise Adams, Valerie L Pushpakom, Sudeep P Pirmohamed, Munir Kemp, Graham J |
| description | Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are effective for obese patients with type 2 diabetes mellitus (T2DM) because they concomitantly target obesity and dysglycaemia. Considering the high prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with T2DM, we determined the impact of 6 months' GLP-1 RA therapy on intrahepatic lipid (IHL) in obese, T2DM patients with hepatic steatosis, and evaluated the inter-relationship between changes in IHL with those in glycosylated haemoglobin (HbA(1)c), body weight, and volume of abdominal visceral and subcutaneous adipose tissue (VAT and SAT). We prospectively studied 25 (12 male) patients, age 50±10 years, BMI 38.4±5.6 kg/m(2) (mean ± SD) with baseline IHL of 28.2% (16.5 to 43.1%) and HbA(1)c of 9.6% (7.9 to 10.7%) (median and interquartile range). Patients treated with metformin and sulphonylureas/DPP-IV inhibitors were given 6 months GLP-1 RA (exenatide, n = 19; liraglutide, n = 6). IHL was quantified by liver proton magnetic resonance spectroscopy ((1)H MRS) and VAT and SAT by whole body magnetic resonance imaging (MRI). Treatment was associated with mean weight loss of 5.0 kg (95% CI 3.5,6.5 kg), mean HbA(1c) reduction of 1·6% (17 mmol/mol) (0·8,2·4%) and a 42% relative reduction in IHL (-59.3, -16.5%). The relative reduction in IHL correlated with that in HbA(1)c (ρ = 0.49; p = 0.01) but was not significantly correlated with that in total body weight, VAT or SAT. The greatest IHL reduction occurred in individuals with highest pre-treatment levels. Mechanistic studies are needed to determine potential direct effects of GLP-1 RA on human liver lipid metabolism. |
| doi_str_mv | 10.1371/journal.pone.0050117 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1339093658</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A477090199</galeid><doaj_id>oai_doaj_org_article_e01c70efda824a5e8bbc489565553af5</doaj_id><sourcerecordid>A477090199</sourcerecordid><originalsourceid>FETCH-LOGICAL-c593t-1f10f352fdd6a34d58fdd870bd93af5d13898a01dee6fe3505a2fb1cc18e1fb93</originalsourceid><addsrcrecordid>eNp1Ul2L1DAULaK46-o_EA34orAdk2bSjxdhWXQdGNAHfQ63yU03Y6epSWZk_oa_2NTpLjugJJDLzTkn54aTZS8ZXTBesfcbt_MD9IvRDbigVFDGqkfZOWt4kZcF5Y8f1GfZsxA2CcTrsnyanRW84CUvi_Ps92o7erdHTbr-oAC3Fohy3mMPEQP5ZeMt6e0ePTEQiUe9U9G6gdiBuBYDXpJ4GJEURFtoMVEuyQjR4hAD6RJvSLo7BZ0b8t7-QDLiGK3GnJG3N-uvOXuXNFXqOU8mkA0xPM-eGOgDvpjPi-z7p4_frj_n6y83q-urda5Ew2PODKOGi8JoXQJfalGnqq5oqxsORmjG66YGyjRiaZALKqAwLVOK1chM2_CL7PVRd-xdkPN3Bsk4b2jDS1EnxOqI0A42cvR2C_4gHVj5t-F8J8FHq3qUSJmqKBoNdbEEgXXbqmXdiFIIMdlJWh_m13btFrVKP-ShPxE9vRnsrezcXnLByrSTwJtZwLufOwzxP5ZnVAfJlR2MS2Jqa4OSV8uqog1lzTT64h-otHQKgEqBMjb1TwjLI0F5F4JHc2-cUTnF8c6MnOIo5zgm2quHQ9-T7vLH_wDYz99N</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1339093658</pqid></control><display><type>article</type><title>Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Cuthbertson, Daniel J ; Irwin, Andrew ; Gardner, Chris J ; Daousi, Christina ; Purewal, Tej ; Furlong, Niall ; Goenka, Niru ; Thomas, E Louise ; Adams, Valerie L ; Pushpakom, Sudeep P ; Pirmohamed, Munir ; Kemp, Graham J</creator><creatorcontrib>Cuthbertson, Daniel J ; Irwin, Andrew ; Gardner, Chris J ; Daousi, Christina ; Purewal, Tej ; Furlong, Niall ; Goenka, Niru ; Thomas, E Louise ; Adams, Valerie L ; Pushpakom, Sudeep P ; Pirmohamed, Munir ; Kemp, Graham J</creatorcontrib><description>Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are effective for obese patients with type 2 diabetes mellitus (T2DM) because they concomitantly target obesity and dysglycaemia. Considering the high prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with T2DM, we determined the impact of 6 months' GLP-1 RA therapy on intrahepatic lipid (IHL) in obese, T2DM patients with hepatic steatosis, and evaluated the inter-relationship between changes in IHL with those in glycosylated haemoglobin (HbA(1)c), body weight, and volume of abdominal visceral and subcutaneous adipose tissue (VAT and SAT). We prospectively studied 25 (12 male) patients, age 50±10 years, BMI 38.4±5.6 kg/m(2) (mean ± SD) with baseline IHL of 28.2% (16.5 to 43.1%) and HbA(1)c of 9.6% (7.9 to 10.7%) (median and interquartile range). Patients treated with metformin and sulphonylureas/DPP-IV inhibitors were given 6 months GLP-1 RA (exenatide, n = 19; liraglutide, n = 6). IHL was quantified by liver proton magnetic resonance spectroscopy ((1)H MRS) and VAT and SAT by whole body magnetic resonance imaging (MRI). Treatment was associated with mean weight loss of 5.0 kg (95% CI 3.5,6.5 kg), mean HbA(1c) reduction of 1·6% (17 mmol/mol) (0·8,2·4%) and a 42% relative reduction in IHL (-59.3, -16.5%). The relative reduction in IHL correlated with that in HbA(1)c (ρ = 0.49; p = 0.01) but was not significantly correlated with that in total body weight, VAT or SAT. The greatest IHL reduction occurred in individuals with highest pre-treatment levels. Mechanistic studies are needed to determine potential direct effects of GLP-1 RA on human liver lipid metabolism.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0050117</identifier><identifier>PMID: 23236362</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adipose tissue ; Adiposity - drug effects ; Adult ; Aging ; Biology ; Biomarkers ; Biopsy ; Blood glucose ; Blood Glucose - drug effects ; Body composition ; Body mass ; Body Mass Index ; Body Weight ; Body weight loss ; Care and treatment ; Chronic illnesses ; Correlation ; Diabetes ; Diabetes mellitus ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - metabolism ; Endocrinology ; Fatty liver ; Fatty Liver - drug therapy ; Fatty Liver - metabolism ; Female ; GLP-1 receptor agonists ; Glucagon ; Glucagon-like peptide 1 ; Glucagon-Like Peptide 1 - agonists ; Glucagon-Like Peptide 1 - analogs & derivatives ; Glucagon-Like Peptide 1 - therapeutic use ; Glycosylated hemoglobin ; Hemoglobin ; Humans ; Hypoglycemic Agents - therapeutic use ; Insulin resistance ; Lipid metabolism ; Liraglutide ; Liver ; Liver - drug effects ; Liver - metabolism ; Liver diseases ; Magnetic resonance ; Magnetic resonance imaging ; Magnetic resonance spectroscopy ; Male ; Measurement techniques ; Medical research ; Medicine ; Metabolism ; Metformin ; Middle Aged ; Nuclear magnetic resonance spectroscopy ; Obesity ; Obesity - drug therapy ; Obesity - metabolism ; Patients ; Peptides - therapeutic use ; Physiological aspects ; Prospective Studies ; Proton magnetic resonance ; Resonance ; Rodents ; Spectroscopy ; Spectrum analysis ; Steatosis ; Type 2 diabetes ; Ultrasonic imaging ; Venoms - therapeutic use ; Weight control ; Weight Loss - drug effects ; Weight reduction</subject><ispartof>PloS one, 2012-12, Vol.7 (12), p.e50117</ispartof><rights>COPYRIGHT 2012 Public Library of Science</rights><rights>2012 Cuthbertson et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2012 Cuthbertson et al 2012 Cuthbertson et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c593t-1f10f352fdd6a34d58fdd870bd93af5d13898a01dee6fe3505a2fb1cc18e1fb93</citedby><cites>FETCH-LOGICAL-c593t-1f10f352fdd6a34d58fdd870bd93af5d13898a01dee6fe3505a2fb1cc18e1fb93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516516/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516516/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79342,79343</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23236362$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cuthbertson, Daniel J</creatorcontrib><creatorcontrib>Irwin, Andrew</creatorcontrib><creatorcontrib>Gardner, Chris J</creatorcontrib><creatorcontrib>Daousi, Christina</creatorcontrib><creatorcontrib>Purewal, Tej</creatorcontrib><creatorcontrib>Furlong, Niall</creatorcontrib><creatorcontrib>Goenka, Niru</creatorcontrib><creatorcontrib>Thomas, E Louise</creatorcontrib><creatorcontrib>Adams, Valerie L</creatorcontrib><creatorcontrib>Pushpakom, Sudeep P</creatorcontrib><creatorcontrib>Pirmohamed, Munir</creatorcontrib><creatorcontrib>Kemp, Graham J</creatorcontrib><title>Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are effective for obese patients with type 2 diabetes mellitus (T2DM) because they concomitantly target obesity and dysglycaemia. Considering the high prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with T2DM, we determined the impact of 6 months' GLP-1 RA therapy on intrahepatic lipid (IHL) in obese, T2DM patients with hepatic steatosis, and evaluated the inter-relationship between changes in IHL with those in glycosylated haemoglobin (HbA(1)c), body weight, and volume of abdominal visceral and subcutaneous adipose tissue (VAT and SAT). We prospectively studied 25 (12 male) patients, age 50±10 years, BMI 38.4±5.6 kg/m(2) (mean ± SD) with baseline IHL of 28.2% (16.5 to 43.1%) and HbA(1)c of 9.6% (7.9 to 10.7%) (median and interquartile range). Patients treated with metformin and sulphonylureas/DPP-IV inhibitors were given 6 months GLP-1 RA (exenatide, n = 19; liraglutide, n = 6). IHL was quantified by liver proton magnetic resonance spectroscopy ((1)H MRS) and VAT and SAT by whole body magnetic resonance imaging (MRI). Treatment was associated with mean weight loss of 5.0 kg (95% CI 3.5,6.5 kg), mean HbA(1c) reduction of 1·6% (17 mmol/mol) (0·8,2·4%) and a 42% relative reduction in IHL (-59.3, -16.5%). The relative reduction in IHL correlated with that in HbA(1)c (ρ = 0.49; p = 0.01) but was not significantly correlated with that in total body weight, VAT or SAT. The greatest IHL reduction occurred in individuals with highest pre-treatment levels. Mechanistic studies are needed to determine potential direct effects of GLP-1 RA on human liver lipid metabolism.</description><subject>Adipose tissue</subject><subject>Adiposity - drug effects</subject><subject>Adult</subject><subject>Aging</subject><subject>Biology</subject><subject>Biomarkers</subject><subject>Biopsy</subject><subject>Blood glucose</subject><subject>Blood Glucose - drug effects</subject><subject>Body composition</subject><subject>Body mass</subject><subject>Body Mass Index</subject><subject>Body Weight</subject><subject>Body weight loss</subject><subject>Care and treatment</subject><subject>Chronic illnesses</subject><subject>Correlation</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - metabolism</subject><subject>Endocrinology</subject><subject>Fatty liver</subject><subject>Fatty Liver - drug therapy</subject><subject>Fatty Liver - metabolism</subject><subject>Female</subject><subject>GLP-1 receptor agonists</subject><subject>Glucagon</subject><subject>Glucagon-like peptide 1</subject><subject>Glucagon-Like Peptide 1 - agonists</subject><subject>Glucagon-Like Peptide 1 - analogs & derivatives</subject><subject>Glucagon-Like Peptide 1 - therapeutic use</subject><subject>Glycosylated hemoglobin</subject><subject>Hemoglobin</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin resistance</subject><subject>Lipid metabolism</subject><subject>Liraglutide</subject><subject>Liver</subject><subject>Liver - drug effects</subject><subject>Liver - metabolism</subject><subject>Liver diseases</subject><subject>Magnetic resonance</subject><subject>Magnetic resonance imaging</subject><subject>Magnetic resonance spectroscopy</subject><subject>Male</subject><subject>Measurement techniques</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Metabolism</subject><subject>Metformin</subject><subject>Middle Aged</subject><subject>Nuclear magnetic resonance spectroscopy</subject><subject>Obesity</subject><subject>Obesity - drug therapy</subject><subject>Obesity - metabolism</subject><subject>Patients</subject><subject>Peptides - therapeutic use</subject><subject>Physiological aspects</subject><subject>Prospective Studies</subject><subject>Proton magnetic resonance</subject><subject>Resonance</subject><subject>Rodents</subject><subject>Spectroscopy</subject><subject>Spectrum analysis</subject><subject>Steatosis</subject><subject>Type 2 diabetes</subject><subject>Ultrasonic imaging</subject><subject>Venoms - therapeutic use</subject><subject>Weight control</subject><subject>Weight Loss - drug effects</subject><subject>Weight reduction</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNp1Ul2L1DAULaK46-o_EA34orAdk2bSjxdhWXQdGNAHfQ63yU03Y6epSWZk_oa_2NTpLjugJJDLzTkn54aTZS8ZXTBesfcbt_MD9IvRDbigVFDGqkfZOWt4kZcF5Y8f1GfZsxA2CcTrsnyanRW84CUvi_Ps92o7erdHTbr-oAC3Fohy3mMPEQP5ZeMt6e0ePTEQiUe9U9G6gdiBuBYDXpJ4GJEURFtoMVEuyQjR4hAD6RJvSLo7BZ0b8t7-QDLiGK3GnJG3N-uvOXuXNFXqOU8mkA0xPM-eGOgDvpjPi-z7p4_frj_n6y83q-urda5Ew2PODKOGi8JoXQJfalGnqq5oqxsORmjG66YGyjRiaZALKqAwLVOK1chM2_CL7PVRd-xdkPN3Bsk4b2jDS1EnxOqI0A42cvR2C_4gHVj5t-F8J8FHq3qUSJmqKBoNdbEEgXXbqmXdiFIIMdlJWh_m13btFrVKP-ShPxE9vRnsrezcXnLByrSTwJtZwLufOwzxP5ZnVAfJlR2MS2Jqa4OSV8uqog1lzTT64h-otHQKgEqBMjb1TwjLI0F5F4JHc2-cUTnF8c6MnOIo5zgm2quHQ9-T7vLH_wDYz99N</recordid><startdate>20121206</startdate><enddate>20121206</enddate><creator>Cuthbertson, Daniel J</creator><creator>Irwin, Andrew</creator><creator>Gardner, Chris J</creator><creator>Daousi, Christina</creator><creator>Purewal, Tej</creator><creator>Furlong, Niall</creator><creator>Goenka, Niru</creator><creator>Thomas, E Louise</creator><creator>Adams, Valerie L</creator><creator>Pushpakom, Sudeep P</creator><creator>Pirmohamed, Munir</creator><creator>Kemp, Graham J</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20121206</creationdate><title>Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists</title><author>Cuthbertson, Daniel J ; Irwin, Andrew ; Gardner, Chris J ; Daousi, Christina ; Purewal, Tej ; Furlong, Niall ; Goenka, Niru ; Thomas, E Louise ; Adams, Valerie L ; Pushpakom, Sudeep P ; Pirmohamed, Munir ; Kemp, Graham J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c593t-1f10f352fdd6a34d58fdd870bd93af5d13898a01dee6fe3505a2fb1cc18e1fb93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adipose tissue</topic><topic>Adiposity - drug effects</topic><topic>Adult</topic><topic>Aging</topic><topic>Biology</topic><topic>Biomarkers</topic><topic>Biopsy</topic><topic>Blood glucose</topic><topic>Blood Glucose - drug effects</topic><topic>Body composition</topic><topic>Body mass</topic><topic>Body Mass Index</topic><topic>Body Weight</topic><topic>Body weight loss</topic><topic>Care and treatment</topic><topic>Chronic illnesses</topic><topic>Correlation</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - metabolism</topic><topic>Endocrinology</topic><topic>Fatty liver</topic><topic>Fatty Liver - drug therapy</topic><topic>Fatty Liver - metabolism</topic><topic>Female</topic><topic>GLP-1 receptor agonists</topic><topic>Glucagon</topic><topic>Glucagon-like peptide 1</topic><topic>Glucagon-Like Peptide 1 - agonists</topic><topic>Glucagon-Like Peptide 1 - analogs & derivatives</topic><topic>Glucagon-Like Peptide 1 - therapeutic use</topic><topic>Glycosylated hemoglobin</topic><topic>Hemoglobin</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin resistance</topic><topic>Lipid metabolism</topic><topic>Liraglutide</topic><topic>Liver</topic><topic>Liver - drug effects</topic><topic>Liver - metabolism</topic><topic>Liver diseases</topic><topic>Magnetic resonance</topic><topic>Magnetic resonance imaging</topic><topic>Magnetic resonance spectroscopy</topic><topic>Male</topic><topic>Measurement techniques</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Metabolism</topic><topic>Metformin</topic><topic>Middle Aged</topic><topic>Nuclear magnetic resonance spectroscopy</topic><topic>Obesity</topic><topic>Obesity - drug therapy</topic><topic>Obesity - metabolism</topic><topic>Patients</topic><topic>Peptides - therapeutic use</topic><topic>Physiological aspects</topic><topic>Prospective Studies</topic><topic>Proton magnetic resonance</topic><topic>Resonance</topic><topic>Rodents</topic><topic>Spectroscopy</topic><topic>Spectrum analysis</topic><topic>Steatosis</topic><topic>Type 2 diabetes</topic><topic>Ultrasonic imaging</topic><topic>Venoms - therapeutic use</topic><topic>Weight control</topic><topic>Weight Loss - drug effects</topic><topic>Weight reduction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cuthbertson, Daniel J</creatorcontrib><creatorcontrib>Irwin, Andrew</creatorcontrib><creatorcontrib>Gardner, Chris J</creatorcontrib><creatorcontrib>Daousi, Christina</creatorcontrib><creatorcontrib>Purewal, Tej</creatorcontrib><creatorcontrib>Furlong, Niall</creatorcontrib><creatorcontrib>Goenka, Niru</creatorcontrib><creatorcontrib>Thomas, E Louise</creatorcontrib><creatorcontrib>Adams, Valerie L</creatorcontrib><creatorcontrib>Pushpakom, Sudeep P</creatorcontrib><creatorcontrib>Pirmohamed, Munir</creatorcontrib><creatorcontrib>Kemp, Graham J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cuthbertson, Daniel J</au><au>Irwin, Andrew</au><au>Gardner, Chris J</au><au>Daousi, Christina</au><au>Purewal, Tej</au><au>Furlong, Niall</au><au>Goenka, Niru</au><au>Thomas, E Louise</au><au>Adams, Valerie L</au><au>Pushpakom, Sudeep P</au><au>Pirmohamed, Munir</au><au>Kemp, Graham J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2012-12-06</date><risdate>2012</risdate><volume>7</volume><issue>12</issue><spage>e50117</spage><pages>e50117-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are effective for obese patients with type 2 diabetes mellitus (T2DM) because they concomitantly target obesity and dysglycaemia. Considering the high prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with T2DM, we determined the impact of 6 months' GLP-1 RA therapy on intrahepatic lipid (IHL) in obese, T2DM patients with hepatic steatosis, and evaluated the inter-relationship between changes in IHL with those in glycosylated haemoglobin (HbA(1)c), body weight, and volume of abdominal visceral and subcutaneous adipose tissue (VAT and SAT). We prospectively studied 25 (12 male) patients, age 50±10 years, BMI 38.4±5.6 kg/m(2) (mean ± SD) with baseline IHL of 28.2% (16.5 to 43.1%) and HbA(1)c of 9.6% (7.9 to 10.7%) (median and interquartile range). Patients treated with metformin and sulphonylureas/DPP-IV inhibitors were given 6 months GLP-1 RA (exenatide, n = 19; liraglutide, n = 6). IHL was quantified by liver proton magnetic resonance spectroscopy ((1)H MRS) and VAT and SAT by whole body magnetic resonance imaging (MRI). Treatment was associated with mean weight loss of 5.0 kg (95% CI 3.5,6.5 kg), mean HbA(1c) reduction of 1·6% (17 mmol/mol) (0·8,2·4%) and a 42% relative reduction in IHL (-59.3, -16.5%). The relative reduction in IHL correlated with that in HbA(1)c (ρ = 0.49; p = 0.01) but was not significantly correlated with that in total body weight, VAT or SAT. The greatest IHL reduction occurred in individuals with highest pre-treatment levels. Mechanistic studies are needed to determine potential direct effects of GLP-1 RA on human liver lipid metabolism.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>23236362</pmid><doi>10.1371/journal.pone.0050117</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2012-12, Vol.7 (12), p.e50117 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1339093658 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Adipose tissue Adiposity - drug effects Adult Aging Biology Biomarkers Biopsy Blood glucose Blood Glucose - drug effects Body composition Body mass Body Mass Index Body Weight Body weight loss Care and treatment Chronic illnesses Correlation Diabetes Diabetes mellitus Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Endocrinology Fatty liver Fatty Liver - drug therapy Fatty Liver - metabolism Female GLP-1 receptor agonists Glucagon Glucagon-like peptide 1 Glucagon-Like Peptide 1 - agonists Glucagon-Like Peptide 1 - analogs & derivatives Glucagon-Like Peptide 1 - therapeutic use Glycosylated hemoglobin Hemoglobin Humans Hypoglycemic Agents - therapeutic use Insulin resistance Lipid metabolism Liraglutide Liver Liver - drug effects Liver - metabolism Liver diseases Magnetic resonance Magnetic resonance imaging Magnetic resonance spectroscopy Male Measurement techniques Medical research Medicine Metabolism Metformin Middle Aged Nuclear magnetic resonance spectroscopy Obesity Obesity - drug therapy Obesity - metabolism Patients Peptides - therapeutic use Physiological aspects Prospective Studies Proton magnetic resonance Resonance Rodents Spectroscopy Spectrum analysis Steatosis Type 2 diabetes Ultrasonic imaging Venoms - therapeutic use Weight control Weight Loss - drug effects Weight reduction |
| title | Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T23%3A08%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improved%20glycaemia%20correlates%20with%20liver%20fat%20reduction%20in%20obese,%20type%202%20diabetes,%20patients%20given%20glucagon-like%20peptide-1%20(GLP-1)%20receptor%20agonists&rft.jtitle=PloS%20one&rft.au=Cuthbertson,%20Daniel%20J&rft.date=2012-12-06&rft.volume=7&rft.issue=12&rft.spage=e50117&rft.pages=e50117-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0050117&rft_dat=%3Cgale_plos_%3EA477090199%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1339093658&rft_id=info:pmid/23236362&rft_galeid=A477090199&rft_doaj_id=oai_doaj_org_article_e01c70efda824a5e8bbc489565553af5&rfr_iscdi=true |